Inflammation Research

, Volume 66, Issue 12, pp 1085–1097 | Cite as

Association of SNPs/haplotypes in promoter of TNF A and IL-10 gene together with life style factors in prostate cancer progression in Indian population

  • Kapil Bandil
  • Pallavi Singhal
  • Atika Dogra
  • Sudhir K. Rawal
  • D. C. Doval
  • Anil K. Varshney
  • Mausumi Bharadwaj
Original Research Paper

Abstract

Objective

Levels of proinflammatory (TNF A) and anti-inflammatory (IL-10) cytokines play a key role in the progression of inflammation as well as cancer disease. We were investigating the potential association of single-nucleotide polymorphisms (SNPs)/haplotypes in proinflammatory (TNF A) and anti-inflammatory (IL-10) cytokines locus with the development of PCa in Indian population.

Materials and methods

We had genotyped 235 BPH/PCa samples (130 BPH and 105 cancer) along with 115 control samples for proinflammatory (TNF A −238G/A and −308G/A) and anti-inflammatory (IL-10 −1082A/G, −819C/T and −592C/A) cytokines SNPs in the gene promoter region using ARMS-PCR method.

Results

Allelic frequencies of TNF A and IL-10 SNPs were found to be significantly associated with the risk of prostate cancer and BPH when compared to controls (p = 0.05). Further haplotypic analysis showed that two haplotypes of TNF A (AG and AA) and IL-10 gene (CCG and CTG) were serving as risk haplotypes for prostate cancer development. IL-10 risk haplotypes were found to be positively associated with aggressiveness of prostate cancer. We also noticed successively increasing percentage of TNF A and IL-10 risk haplotypes with life style habits like smoking (10 and 26%) and alcohol consuming (9 and 27%).

Conclusions

According to our data, TNF A −238G>A and IL-10 −1082A>G, −819C>T and −592C>A may be associated with the development of prostate cancer and BPH. We could also notice higher frequency of TNF A and IL-10 risk haplotypes in smoker and alcohol user. Interestingly, IL-10 risk haplotype was positively associated with aggressiveness of tumor. This information can be used for the early diagnosis of disease and to improve tissue-specific treatment’s efficacy which will be moving ultimately towards the discovery of personalized therapy.

Keywords

Prostate cancer TNF A IL-10 Haplotype 

Notes

Acknowledgements

The authors thank patients, their relatives, and clinicians for their support and cooperation. The study was supported by funds provided by NICPR-ICMR, Noida to MB.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

11_2017_1088_MOESM1_ESM.docx (23 kb)
Supplementary material 1 (DOCX 23 kb)

References

  1. 1.
    Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–27.CrossRefPubMedGoogle Scholar
  2. 2.
    Takiar R, Kumar S. Pattern of reproductive cancers in India. Asian Pac J Cancer Prev. 2014;15:599–603.CrossRefPubMedGoogle Scholar
  3. 3.
    Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: current status. J Natl Cancer Inst. 1999;91:414–28.CrossRefPubMedGoogle Scholar
  4. 4.
    Hickey K, Do KA, Green A. Smoking and prostate cancer. Epidemiol Rev. 2001;23:115–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Bandil K, Singhal P, Sharma U, Hussain S, Basu S, Parashari A, et al. Impacts of TNF-LTA SNPs/haplotypes and lifestyle factors on oral carcinoma in an indian population. Mol Diagn Ther. 2016;20:469–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Kohaar I, Thakur N, Salhan S, Batra S, Singh V, Sharma A, et al. TNFalpha −308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol. 2007;29:249–56.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Kohaar I, Tiwari P, Kumar R, Nasare V, Thakur N, Das BC, et al. Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population. Breast Cancer Res Treat. 2009;114:347–55.CrossRefPubMedGoogle Scholar
  8. 8.
    Korobeinikova E, Myrzaliyeva D, Ugenskiene R, Raulinaityte D, Gedminaite J, Smigelskas K, et al. The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients. BMC Genet. 2015;16:70.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Singhal P, Kumar A, Bharadwaj S, Hussain S, Bharadwaj M. Association of IL-10 GTC haplotype with serum level and HPV infection in the development of cervical carcinoma. Tumour Biol. 2014;36:2287–98.CrossRefPubMedGoogle Scholar
  10. 10.
    Crawley E, Woo P, Isenberg DA. Single nucleotide polymorphic haplotypes of the interleukin-10 5′ flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus. Arthritis Rheum. 1999;42:2017–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Kingo K, Ratsep R, Koks S, Karelson M, Silm H, Vasar E. Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci. 2005;37:111–3.CrossRefPubMedGoogle Scholar
  12. 12.
    Ma L, Zhao J, Li T, He Y, Wang J, Xie L, et al. Association between tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol. 2014;9:74.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kirkpatrick A, Bidwell J, van den Brule AJ, Meijer CJ, Pawade J, Glew S. TNFalpha polymorphism frequencies in HPV-associated cervical dysplasia. Gynecol Oncol. 2004;92:675–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics. 1997;46:120–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Hsu HJ, Yang YH, Shieh TY, Chen CH, Kao YH, Yang CF, et al. TGF-beta1 and IL-10 single nucleotide polymorphisms as risk factors for oral cancer in Taiwanese. Kaohsiung J Med Sci. 2015;31:123–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Kesarwani P, Ahirwar DK, Mandhani A, Singh AN, Dalela D, Srivastava AN, et al. IL-10 −1082 G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol. 2009;27:389–96.CrossRefPubMedGoogle Scholar
  18. 18.
    Liu J, Song B, Bai X, Liu W, Li Z, Wang J, et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer. 2010;10:456.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124:1193–201.CrossRefPubMedGoogle Scholar
  20. 20.
    Nikolova PN, Pawelec GP, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN, et al. Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother. 2007;56:371–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58–64.CrossRefPubMedGoogle Scholar
  22. 22.
    Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold spring harbor laboratory press; 1989.Google Scholar
  23. 23.
    Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun. 2001;2:25–31.CrossRefPubMedGoogle Scholar
  24. 24.
    Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273:1516–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun. 2001;2:61–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Kroeger KM, Carville KS, Abraham LJ. The −308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Horvat V, Sudarevic B, Cosic I, Milicevic N, Bosnjak S, Mandic S, et al. Lack of association between TNF-alpha promoter polymorphism and prostate carcinoma susceptibility in eastern Croatian population. Coll Antropol. 2014;37:1199–202.Google Scholar
  29. 29.
    Wang J, Cao C, Luo H, Xiong S, Xu Y, Xiong W. Tumour necrosis factor alpha −308G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int J Immunogenet. 2011;38:311–20.CrossRefPubMedGoogle Scholar
  30. 30.
    Shao N, Xu B, Mi YY, Hua LX. IL-10 polymorphisms and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis. 2011;14:129–35.CrossRefPubMedGoogle Scholar
  31. 31.
    Ahirwar D, Mandhani A, Mittal RD. Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer. Arch Med Res. 2009;40:97–102.CrossRefPubMedGoogle Scholar
  32. 32.
    Howell WM, Rose-Zerilli MJ. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer. 2006;5:143–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control. 2008;19:119–24.CrossRefPubMedGoogle Scholar
  34. 34.
    McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002;62:3369–72.PubMedGoogle Scholar
  35. 35.
    Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, et al. The interleukin-10 (−1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. Anticancer Res. 2008;28:309–14.PubMedGoogle Scholar
  36. 36.
    Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res. 2006;66:4525–30.CrossRefPubMedGoogle Scholar
  37. 37.
    Zou YF, Wang F, Feng XL, Tian YH, Tao JH, Pan FM, et al. Lack of association of IL-10 gene polymorphisms with prostate cancer: evidence from 11,581 subjects. Eur J Cancer. 2011;47:1072–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Joshi MS, Verma Y, Gautam AK, Parmar G, Lakkad BC, Kumar S. Cytogenetic alterations in buccal mucosa cells of chewers of areca nut and tobacco. Arch Oral Biol. 2010;56:63–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Pacheco SO, Pacheco FJ, Zapata GM, Garcia JM, Previale CA, Cura HE, et al. Food habits, lifestyle factors, and risk of prostate cancer in Central Argentina: a case control study involving self-motivated health behavior modifications after diagnosis. Nutrients. 2016;8(7):1–22. doi: 10.3390/nu8070419.CrossRefGoogle Scholar
  40. 40.
    Haddy N, Sass C, Maumus S, Marie B, Droesch S, Siest G, et al. Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur J Hum Genet. 2005;13:109–17.CrossRefPubMedGoogle Scholar
  41. 41.
    Lambert C, McCue J, Portas M, Ouyang Y, Li J, Rosano TG, et al. Acrolein in cigarette smoke inhibits T-cell responses. J Allergy Clin Immunol. 2005;116:916–22.CrossRefPubMedGoogle Scholar
  42. 42.
    Mian MF, Lauzon NM, Stampfli MR, Mossman KL, Ashkar AA. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J Leukoc Biol. 2008;83:774–84.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Kapil Bandil
    • 1
    • 2
  • Pallavi Singhal
    • 1
  • Atika Dogra
    • 3
  • Sudhir K. Rawal
    • 4
  • D. C. Doval
    • 5
  • Anil K. Varshney
    • 6
  • Mausumi Bharadwaj
    • 1
    • 2
  1. 1.Division of Molecular Genetics and BiochemistryNational Institute of Cancer Prevention and Research (ICMR)NoidaIndia
  2. 2.Dr. A.P.J. Abdul Kalam Technical UniversityLucknowIndia
  3. 3.Research DepartmentRajiv Gandhi Cancer Institute and Research CentreNew DelhiIndia
  4. 4.Surgical Gynae Uro-OncologyRajiv Gandhi Cancer Institute and Research CentreNew DelhiIndia
  5. 5.Medical OncologyRajiv Gandhi Cancer Institute and Research CentreNew DelhiIndia
  6. 6.R. G. Stone Urology and Laparoscopy HospitalNew DelhiIndia

Personalised recommendations